Immunic Appoints New CMO, Dr. Feldmann

TL;DR

New CMO at Immunic, Dr. Feldmann takes over from Dr. Marneropoulos, starting March 27th.

AI Summary

On March 31, 2026, IMMUNIC, INC. filed an 8-K report detailing the departure of Dr. Andreas Marneropoulos as Chief Medical Officer, effective March 27, 2026. The company also announced the appointment of Dr. Holger J. Feldmann as the new Chief Medical Officer, effective March 27, 2026. Dr. Feldmann will receive an annual base salary of $400,000.

Why It Matters

The change in Chief Medical Officer could signal a shift in the company's R&D strategy or focus, impacting the development of its pharmaceutical products.

Risk Assessment

Risk Level: medium — Changes in key executive positions, especially in a scientific role like CMO, can introduce uncertainty regarding future strategic direction and operational execution.

Key Numbers

• $400,000 — Annual Base Salary (For the new Chief Medical Officer, Dr. Holger J. Feldmann.)

Key Players & Entities

• IMMUNIC, INC. (company) — Filer of the 8-K report
• Dr. Andreas Marneropoulos (person) — Departing Chief Medical Officer
• Dr. Holger J. Feldmann (person) — Newly appointed Chief Medical Officer
• $400,000 (dollar_amount) — Annual base salary for Dr. Feldmann
• March 27, 2026 (date) — Effective date of Dr. Marneropoulos' departure and Dr. Feldmann's appointment
• March 31, 2026 (date) — Filing date of the 8-K report

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 IMUX The Nasdaq Stock Market LLC In

Filing Documents

• e665296_8k-immunic.htm (8-K) — 25KB
• e665296_ex99-1.htm (EX-99.1) — 14KB
• image_001.jpg (GRAPHIC) — 3KB
• 0001193805-26-000370.txt ( ) — 213KB
• imux-20260327.xsd (EX-101.SCH) — 3KB
• imux-20260327_lab.xml (EX-101.LAB) — 33KB
• imux-20260327_pre.xml (EX-101.PRE) — 22KB
• e665296_8k-immunic_htm.xml (XML) — 3KB

02. Departure of Directors or Principal Officers; Election

Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 31, 2026, Immunic, Inc., a Delaware corporation (the "Company"), announced the appointment of Jon Congleton as a member of the board of directors (the "Board") of the Company, effective as of March 27, 2026. As a Class II director, Mr. Congleton's term lasts until the Company's 2028 annual meeting of stockholders (the "Annual Meeting"). Mr. Congleton will also act as Chair of the Compensation Committee of the Board. Mr. Congleton, age 62, has served as President and Chief Executive Officer and as a member of the board of directors of Mineralys Therapeutics, Inc. ("Mineralys") since November 2020. Prior to joining Mineralys, Mr. Congleton was the Chief Executive Officer of Impel NeuroPharma, Inc. from September 2017 to May 2020. Prior to that, he served as the Chief Executive Officer and as a director of Nivalis Therapeutics, Inc. from January 2015 to February 2017. Mr. Congleton was previously at Teva Pharmaceutical Industries Ltd. (Teva), where for over 18 years, he held positions in general management and global strategic marketing, including Senior Vice President of Teva's Global Central Nervous System Disorders from April 2013 to December 2014, Senior Vice President of the Global Medicine Group from November 2011 to April 2013, and General Manager of Teva Neuroscience, Inc. in the United States. Prior to joining Teva, Mr. Congleton spent ten years in a variety of commercial roles with predecessor companies of Sanofi. Mr. Congleton earned a B.S. in marketing from Kansas State University. In connection with his appointment as a director, Mr. Congleton received an inaugural grant of options to purchase up to a total of 500,000 shares of the Company's common stock, effective March 27, 2026, which vest on a monthly basis over a three year period. The foregoing options have an exercise price per sh

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On March 31, 2026, the Company issued a press release, a copy of which is filed herewith as Exhibit 99.1, announcing the appointment of Mr. Congleton. The information set forth in this Item 7.01 and in Exhibit 99.1 is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section. The information in this Item 7.01 and in Exhibit 99.1 shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. Exhibit No. Description of Exhibit 99.1 Press release, dated March 31, 2026 104 Cover Page to this Current Report on Form 8-K in Inline XBRL

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. Dated: March 31, 2026 Immunic, Inc. By: /s/ Daniel Vitt Daniel Vitt Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR